These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21187604)

  • 1. [Measurement of bone mineral density is necessary for monitoring of bisphosphonate treatment].
    Soen S
    Clin Calcium; 2011 Jan; 21(1):116-9. PubMed ID: 21187604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Measurement of bone mineral density is unnecessary for monitoring of bisphosphonate treatment].
    Nishida A; Ito M
    Clin Calcium; 2011 Jan; 21(1):120-3. PubMed ID: 21187605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
    Hochberg MC; Ross PD; Black D; Cummings SR; Genant HK; Nevitt MC; Barrett-Connor E; Musliner T; Thompson D
    Arthritis Rheum; 1999 Jun; 42(6):1246-54. PubMed ID: 10366118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New development in bisphosphonate treatment. Bisphosphonates for the treatment of glucocorticoid-induced osteoporosis].
    Soen S
    Clin Calcium; 2009 Jan; 19(1):44-53. PubMed ID: 19122264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial.
    Bauer DC; Black DM; Garnero P; Hochberg M; Ott S; Orloff J; Thompson DE; Ewing SK; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1250-8. PubMed ID: 15231011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bone diseases with Pain. Osteoporosis].
    Hayashi Y
    Clin Calcium; 2007 Apr; 17(4):606-12. PubMed ID: 17404492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How should clinicians manage osteoporosis in ankylosing spondylitis?
    Bessant R; Keat A
    J Rheumatol; 2002 Jul; 29(7):1511-9. PubMed ID: 12136913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
    Chen P; Miller PD; Delmas PD; Misurski DA; Krege JH
    J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
    Fukunaga M
    Clin Calcium; 2009 Jan; 19(1):63-73. PubMed ID: 19122266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
    Sarkar S; Mitlak BH; Wong M; Stock JL; Black DM; Harper KD
    J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One fracture is enough! Experience with a prospective and consecutive osteoporosis screening program with 239 fracture patients.
    Astrand J; Thorngren KG; Tägil M
    Acta Orthop; 2006 Feb; 77(1):3-8. PubMed ID: 16534695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Alendronate for treatment of osteoporoses].
    Harada A
    Nihon Rinsho; 2009 May; 67(5):943-7. PubMed ID: 19432114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bone mineral density and fracture risk in patients with ankylosing spondylitis].
    Madsen OR
    Ugeskr Laeger; 2008 Nov; 170(48):3956-60. PubMed ID: 19087736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?
    Bonnick SL; Shulman L
    Am J Med; 2006 Apr; 119(4 Suppl 1):S25-31. PubMed ID: 16563938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bisphosphontes].
    Ichimura S
    Clin Calcium; 2005 Apr; 15(4):583-90. PubMed ID: 15802769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comprehensive review of treatments for postmenopausal osteoporosis.
    Häuselmann HJ; Rizzoli R
    Osteoporos Int; 2003 Jan; 14(1):2-12. PubMed ID: 12577179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
    N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.